People with NNRTI resistance have poorer responses to dolutegravir, South African study finds
People with HIV who already have resistance to a non-nucleoside reverse transcriptase inhibitor (NNRTI) when they start first-line antiretroviral treatment containing the integrase inhibitor dolutegravir were less likely to achieve viral suppression, a large clinical trial in South Africa has reported. NNRTI resistance has not been shown to affect responses to dolutegravir-based treatment previously. The… Read More »
